Feds Warn Savannah Chrisley: The Crackdown on False and Misleading Weight Loss Marketing

The way it played out was almost predictable. A website full of phrases intended to sound authoritative and clinical, a wellness brand centered around injectable weight loss medications, a young celebrity with a sizable social media following—and then a letter from the federal government. Savannah Chrisley, who gained notoriety for growing up in front of cameras on Chrisley Knows Best, received an FDA warning earlier this year. The reasons behind this warning reveal something far more significant than a reality star’s side gig.

In February, the FDA examined Chrisley’s GoodGirlRX website and found that certain language went too far. Phrases such as “FDA-approved meds,” “FDA-approved options,” and “clinically proven GLP-1 results” were being used in relation to compounded versions of tirzepatide and semaglutide, which have never been approved by the FDA. The agency’s stance was clear: such language suggests a degree of official safety and efficacy evaluation that these products just do not have. Chrisley had fifteen business days to reply and make the necessary corrections.

The website was updated by her. The phrase now states “clinically studied results,” and disclaimers stating that the products are not FDA-approved have been added. Although it’s a small change in wording, that’s precisely the kind of distinction that distinguishes compliance from ongoing risk in terms of regulations. Another question—possibly the more uncomfortable one—is whether or not customers who scroll past those disclaimers truly notice the difference.

Chrisley herself isn’t the main reason this case merits consideration. It’s the background. Her warning was one of thirty that the FDA sent out at the same time to businesses that were marketing compounded GLP-1 products in ways that might trick customers into thinking they were buying the same drugs under brand names like Wegovy, Ozempic, or Mounjaro. It seems that some companies branded their compounded versions in a way that made the difference nearly undetectable. FDA Commissioner Marty Makary referred to the initiative as a “new era of enforcement” that targets deceptive pharmaceutical marketing on media platforms. This description implies that this is more of a long-term campaign than a one-time event.

It’s difficult to ignore how perfectly timed everything seems. GLP-1 drugs have become one of the most talked-about drug classes in recent years, bringing in billions of dollars and changing discussions about medicine, health, and weight. Numerous telehealth companies jumped at the chance created by this popularity; some were cautious, while others weren’t. Celebrity endorsements significantly increased these products’ visibility. The average person isn’t reading the fine print regarding compounding pharmacies and federal approval status when someone with millions of followers advertises a weight-loss medication on Instagram or through a branded website. They see a promise and a familiar face.

Perhaps more concerning is the bigger picture. In a recent letter to acting FDA Commissioner Sara Brenner, Senator Jim Banks of Indiana warned about an increase in fake and knockoff GLP-1 drugs entering the nation, many of which contain active pharmaceutical ingredients manufactured abroad that have never been assessed by US regulators. By the end of last year, the FDA’s own Adverse Event Reporting System had documented over 900 cases of adverse health events associated with these medications, which is four times the number recorded in fiscal 2022, according to Banks’s letter. In seventeen of those cases, there were fatalities. These are not impersonal regulatory issues. These consequences have an impact on actual people who thought they were purchasing something secure.

The FDA’s current enforcement strategy is similar to previous Federal Trade Commission initiatives aimed at misleading weight loss advertising. Although some questioned their scope, those campaigns did change behavior in quantifiable ways by combining industry guidelines with real enforcement action. The GLP-1 market is so much bigger than anything the FTC was managing ten years ago, and social media has made celebrity-backed health marketing quicker and more difficult to track than traditional advertising ever was. As a result, there is a feeling that the current effort is being implemented with greater urgency.

The Savannah Chrisley situation is likely clarifying for wellness brands associated with celebrities. Although the FTC has previously pursued celebrity endorsers, the notion that a well-known brand shields it from regulatory scrutiny has always been dubious. This round of FDA warnings makes it clear that the agency is paying much more attention to online health marketing than it used to, and that the language used on a telehealth website matters in a very specific legal sense. “FDA-approved” and “clinically studied” are not synonymous terms. There is actual risk when using them as such, even informally.

Chrisley, on the other hand, seems to have adapted swiftly. How carefully the site’s marketing is handled moving forward will probably determine whether GoodGirlRX can continue to function without additional scrutiny. It’s still unclear if the modifications she made will satisfy federal regulators completely or if there will be further review. However, it appears increasingly certain that the days of celebrity wellness companies operating in a largely unregulated gray area are coming to an end, and the federal government appears genuinely committed to making that point, at least for the time being.